STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (May 2022)
27 slides from STRATA Skin Sciences's investor presentation, May 19, 2022
Slide 1: Driving Value to Dermatology Partners Matching Patients with Clinics
Investor Presentation December 2020 Investor Presentation May 2022 Driving Value to Dermatology Partners Matching Patients with Clinics
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,”
Slide 3: Investment highlights: large markets and recurring revenue model
3 Source: 1 Market Data Forecast Report 2021, Fortune Business Insights 2018, 2019 Addressing large markets for chronic skin diseases with differentiated laser-based treatments Recurring revenue model drives repeat and sustainable revenues Customer base of ~1K partner practices and growing Sales dri
Slide 4: Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions
Positioned for Growth Acceleration in the Treatment of Chronic Skin Conditions 4 CEO CFO VP Marketing VP of Professional Relations Head of International Sales Director of Business Operations 3 new Board Members New Leadership Commercial Focus and Execution Acquisitions DTC marketing analytics Direct
Slide 5: Chronic Dermatologic Conditions Treated with XTRAC Excimer Laser
Chronic Dermatologic Conditions Treated with XTRAC Excimer Laser 5 ECZEMA PSORIASIS VITILIGO PSORIASIS: Autoimmune disease that causes the skin to regenerate faster than normal; characterized by red, itchy scaly patches (65% Mild; 25% Moderate; 10% Severe) ~8 Million patients in the U.S.3 VITILIGO:
Slide 6: XTRAC Treatments by Indication – United States
XTRAC® Treatments by Indication – United States 6 5% 80% 15% Opportunities exist for expanding use for other approved indications Vitiligo Eczema (Atopic Dermatitis) #1use for XTRAC® lasers domestically Psoriasis treatments remain
Slide 7: XTRAC: Psoriasis
XTRAC®: Psoriasis 7 After 4 tx After 2 tx Baseline Clinical Protocol – 6.2 treatments to PASI 75 Beam of UVB light applied to the affected area PASI – A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trial
Slide 8: XTRAC: Vitiligo
XTRAC®: Vitiligo 8 Beam of UVB light applied to the affected area XTRAC®The solution for Vitiligo Results in re-pigmentation UVB light reduces the immune system’s attack on the melanocytes Simple, safe, effective + long-lasting Excimer laser Baseline After 18 tx After 29 tx
Slide 9: Multicenter Psoriasis Study and Sample Studies from 150+ Clinical Studies
Multicenter Psoriasis Study7 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or better after 10
Slide 10: Treatment Options Addressing Psoriasis Indication
Treatment Options Addressing Psoriasis Indication6 10 XTRAC NB-UVB* Topical Steroids Non-biologic Systemics Biologics Approximate Costs ($) Cost competitive 1K-3K 3K-9K 1K -7K 1K 32K-68K Clinical Impact Better clinical outcomes (PASI%75) 92% 71% 75% 48% 50-70% Speed of Onset (in weeks) Very fast rat
Slide 11: XTRAC is the Leader in Targeted 308nm Excimer Laser Therapy
Best-in-class Excimer TREATMENT XTRAC® is the Leader in Targeted 308nm Excimer Laser Therapy 11 Safe & Effective Treatment 150+ Peer-Reviewed Clinical Studies Economical for Patients and Payors Win-Win for Providers and their Patients
Slide 12: Growing Installed Base Drives Recurring Revenue Model
Growing Installed Base Drives Recurring Revenue Model 12 Systems FY 19 Systems FY 20 Systems FY 21 Net Installed Base Growth 2019 – 1Q 2022 28% growth in installed base over the last 3+ years Actively redeploying under utilized devices Group placements and Ra Medical conversions drive growth +160 -7
Slide 13: A True Partnership – Delivering a Complete Business Solution
A True Partnership – Delivering a Complete Business Solution 13 Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Assistance DTC Marketing
Slide 14: Key Priority: Driving Commercial Execution
Key Priority: Driving Commercial Execution 14 Sustain investment in DTC marketing Continue to focus and grow high-volume accounts Drive increased utilization across all indications Increase marketing to drive awareness among derms Historical trends show positive correlation between DTC investment an
Slide 15: Domestic Market: Sales and Service Engine
Domestic Market: – Sales and Service Engine Overview 4 Regions 30 Sales Territories 2 National Account Managers 15 Field Service Techs In-House Call Center to Qualify Leads Predominant Provider of Excimer Laser Treatments 15 Territories color coded
Slide 16: XTRAC Installed Base – Multiple Growth Drivers
XTRAC® Installed Base – Multiple Growth Drivers International Current Markets: China, Japan, Saudi Arabia, S. Korea, Israel Insurance covered in most markets Usage per device higher than U.S. market 1,300 devices sold and in service 55 International partner XTRAC® clinics (up from 10 in 2019) 16 1,9
Slide 17: Acquired the U.S. Dermatology Business of Ra Medical Systems
Acquired the U.S. Dermatology Business of Ra Medical Systems 17 Provides STRATA with the opportunity to market its full business solution to Ra Medical’s existing customer base of 250+ active accounts Positions STRATA as the predominant provider of excimer laser treatments in the U.S. Thru 03/31/202
Slide 18: Theraclear Acquisition
Theraclear Acquisition 18 Substantially broadens STRATA’s opportunity with expansion potential into the estimated $5.5B acne care market Creates robust pipeline of opportunities to target conditions beyond acne with a unique light treatment approach Reinforces STRATA’s vision to be the premier provi
Slide 19: TheraClearX Acne System
TheraClear®X Acne System The TheraClearX Acne System is FDA cleared for the treatment of multiple acne forms ● Acne Vulgaris ● Pustular Acne ● Comedonal Acne Dual mechanism of action (MOA) combining negative pressure vacuum with pulsed broadband light delivered through a liquid cooled, handheld deli
Slide 20: Executive Management Team: 100+ yrs. dermatology experience
Executive Management Team: 100+ yrs. dermatology experience Robert (Bob) J. Moccia, CEO Encore Dermatology, Precision Dermatology, Medicis Pharmaceuticals, Graceway Pharmaceuticals, Bioglan Pharmaceuticals, Stiefel Laboratories, Dermik Laboratories (RPR) Chris Lesovitz, CFO Encore Dermatology, Iroko
Slide 21: Financial Metrics
Financial Metrics 21 * Unaudited quarterly results 2018 2019 2020 Q1 '21* Q2 '21* Q3 '21* Q4 '21* 2021 Q1’22* Recurring revenue $21,053 $23,713 $17,409 $4,679 $5,452 $5,710 $6,687 $22,528 $5,067 Equipment revenue $8,802 $7,873 $5,681 $1,148 $1,930 $2,001 $2,370 $7,449 $1,974 Total revenue $29,855 $3
Slide 22: Commercial Drivers in 2022
Commercial Drivers in 2022 22 Continue DTC advertising campaign with social media XTRAC® Awareness: Co-Op advertising to suitable patients (digital + print) Develop patient advocacy partnerships Broadened commercial strategy to expand use within partner practices Added emphasis on professional relat
Slide 23: STRATA Key Investment Takeaways
STRATA Key Investment Takeaways 23 Differentiated Treatment providing a Win-Win-Win for Patients + Clinics + Payers Addressing Large and Growing Markets + Positioned for Inorganic Growth Proven Business Model to Expand + Achieve Sustainable Results and Shareholder Returns
Slide 24: Thank You
Investor Presentation December 2020 Thank You
Slide 25: Appendix
Investor Presentation December 2020 Appendix
Slide 26: Board of Directors
Board of Directors William Humphries Chairman of the Board and Governance & Compensation Committee CEO, Isosceles Pharmaceuticals, Inc. former President & Group Chairman Ortho Dermatologics, Merz Pharmaceuticals, Stiefel Pharmaceuticals, Allergan Pharmaceuticals Dr. Uri Geiger CEO Accelmed Inc. CEO
Slide 27: Partner Academic Institutions
Partner Academic Institutions 27
STRATA Skin Sciences — Investor Presentation (May 2022) on 6ix